Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018

  • ID: 4517457
  • Report
  • 152 pages
  • DelveInsight
UP TO OFF
until Dec 31st 2018
1 of 4

FEATURED COMPANIES

  • AbbVie
  • ArQule
  • Carna Biosciences
  • Hanmi Pharmaceutical
  • Merck
  • Roche
  • MORE
Bruton's Tyrosine Kinase (BTK) Inhibitors - Competitive Landscape, Pipeline and Market Analysis, 2018 provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 30+ products along with 25+ companies involved. Acerta Pharma and BeiGene are developing therapeutic drugs in the higher phase and Acerta Pharma has been granted both Orphan and Breakthrough Therapy Designation from FDA.

Products covered by Phase:
  • Filed, Phase III, Phase II and Phase I
  • IND and Pre-clinical
Overview of pipeline development activities for Bruton's Tyrosine Kinase (BTK) Inhibitors

Pipeline analysis of 30+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.
Therapeutic segmentation of products for Bruton's Tyrosine Kinase (BTK) Inhibitors
The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

Methodology:

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by the researcher's team of industry experts.
Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Scope:
  • The report provides competitive pipeline landscape of Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides the marketed drugs information including its sales, development activities and details of patent expiry
  • The report provides the insight of current and future market for Bruton's Tyrosine Kinase (BTK) Inhibitors
  • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
  • Coverage of the Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
  • The report reviews key players involved in the therapeutics development for Bruton's Tyrosine Kinase (BTK) Inhibitors and also provide company profiling
  • Pipeline products coverage based on various stages of development ranging from late stage till pre-clinical stage
  • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type
Reasons to Buy:
  • Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage
  • Establish a comprehensive understanding of the current pipeline scenario Bruton's Tyrosine Kinase (BTK) Inhibitors to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Bruton's Tyrosine Kinase (BTK) Inhibitors R&D
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
  • Devise corrective measures for pipeline projects by understanding Bruton's Tyrosine Kinase (BTK) Inhibitors pipeline depth and focus of target therapeutics
  • Developing strategic initiatives to support your drug development activities
  • Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Bruton's Tyrosine Kinase (BTK) Inhibitors to enhance and expand business potential and scope
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs
  • Gaining a full picture of the Competitive Landscape for Evidence based Decisions
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • ArQule
  • Carna Biosciences
  • Hanmi Pharmaceutical
  • Merck
  • Roche
  • MORE
Report Highlights
Executive Summary
Collaborations
Technology
Overview
Structure of Bruton’s Tyrosine Kinase
Mechanism of Action
Expression of BTK
BTK Mutations
Bruton’s Tyrosine Kinase Inhibitor
BTK Inhibitors Role in Oncology
BTK Inhibitors Role in Autoimmune Diseases
Competitive Landscape - Active Drugs
Marketed and Pipeline Drugs
Marketed Drugs
Imbruvica: Janssen
Product Description
Research and Development
Product Development Activities
Drug Sales
Imbruvica - Heat Map
Analyst Insights: Imbruvica
Competitive landscape for Imbruvica
Sales of Imbruvica
Clinical Future of Imbruvica
BTK Inhibitors Market Evolution
BTK Inhibitors Class Share Evolution
Pipeline Therapeutics (Active Products)
Comparative Analysis
Late Stage Products (Filed & Phase III)
Comparative Analysis
ACP-196: Acerta Pharma
Product Description
Research and Development
Product Development Activities
Drug Sales
(The list continues)
Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I and IND)
Comparative Analysis
Pre-clinical Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Stage and Molecule Type
Inactive Products
Other Inactive Products
Gist of BTK Inhibitors
List of Product
List of companies
Appendix

List of Tables
Table 1: Marketed and Pipeline BTK Inhibitors
Table 2: Total Products for BTK Inhibitors
Table 3: Late Stage Products (Phase III)
Table 4: Mid Stage Products (Phase II)
Table 5: Early Stage Products (Phase I and IND)
Table 6: Pre-clinical Stage Products
Table 7: Assessment by Monotherapy Products
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Stage and Molecule Type
Table 11: List of Dormant Products
Table 12: Other Inactive Products

List of Figures
Figure 1: Structure of Bruton’s Tyrosine Kinase
Figure 2: Involvement of BTK in B cell receptor signaling
Figure 3: Marketed and Pipeline BTK Inhibitors
Figure 4: Market Evolution (2013-2022)
Figure 5: Total Products for BTK Inhibitors
Figure 6: Late Stage Products (Filed & Phase III)
Figure 7: Mid Stage Products (Phase II)
Figure 8: Early Stage Products (Phase I and IND)
Figure 9: Pre-clinical Stage Products
Figure 10: Assessment by Monotherapy Products
Figure 11: Assessment by Route of Administration
Figure 12: Assessment by Stage and Route of Administration
Figure 13: Assessment by Stage and Molecule Type
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • ACEA Biosciences
  • Acerta Pharma
  • Aptose Biosciences
  • ArQule
  • BeiGene
  • Biogen
  • Bristol- Myers Squibb
  • Carna Biosciences
  • Celgene Corporation
  • Eternity Bioscience
  • Gilead Sciences
  • Hanmi Pharmaceutical
  • KBP Biosciences
  • Loxo Oncology
  • LSK BioPharma
  • Merck
  • Ono Pharmaceutical
  • Pharmacyclics
  • Principia Biopharma
  • Roche
  • Sunesis
  • Takeda
  • Tolero
  • X-Rx
  • Zhejiang DTRM Biopharma
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll